Print this page    •   Back to Web version of article

Fact Sheet
TDF2 Study of Pre-Exposure Prophylaxis (PrEP) Among Heterosexual Men and Women in Botswana: Key Facts

July 14, 2011

Overview


Trial Design and Study Population


Study Results

Efficacy

Adherence and Risk Behavior

Safety and Resistance


Resources


Footnotes

  1. In this analysis, the follow-up period for all participants was 30 days after the date of their last reported drug dose. This follow-up period was used to ensure detection of all acute HIV infections that may have occurred while a participant had a supply of study medication.
  2. In this analysis, the follow-up period for all participants was 30 days after the date of their last reported drug dose. All participants received a 30-day supply of study medications at each monthly study visit and were asked to return any unused medication from the prior visit at that time. At the visit when the participant's final supply of study drugs was returned, participants were also asked the date on which they took their last study pill. Participants were followed for an additional 30 days from this date to ensure detection of all acute HIV infections that could have occurred while the participant had a supply of study drugs.




This article was provided by U.S. Centers for Disease Control and Prevention. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/62964/tdf2-study-of-pre-exposure-prophylaxis-prep-among-.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.